Biotech grants in South Korea

Open

Funds research teams building low-cost, simplified pathogen-sequencing workflows that bring the cost of sequencing a sample down to about US$1-10 for use in low- and middle-income countries.

Funds teams up to $800,000 to build cheap pathogen-sequencing workflows for poorer countries.

Open

Funds one centre that trains researchers in formal drug development for substance use disorder and pays to test their best ideas.

Open

Funds high-risk clinical trials of new ways to see inside the living human inner ear. A trial is compulsory, and NIH stays in the room.

Open

Funds building the imaging that can finally show hair cells and membranes inside a living human ear. A clinical trial is optional.

Open

Funds researchers combining computational and experimental approaches to test repositioned drugs for Alzheimer's disease treatment through NIH R01 grants.

Open

Funds an addition to an existing NIH grant, to take a cancer biomarker assay from working in the lab to working in the clinic.

Open

Supports early-career clinician scientists with protected salary time to launch Friedreich's ataxia translational research careers.

Open

Funds Friedreich ataxia research on disease mechanisms and translational targets.

Open

Supports postdoctoral and graduate researchers entering new Friedreich ataxia studies.

Open

Funds the enhancement of a cancer informatics tool that has cleared prototyping, shows real promise, and has not yet been widely adopted.

Open

Funds the running costs and continued relevance of a cancer informatics tool that researchers already depend on.

Open

Funds foreign and domestic entities running rare-disease clinical trials through FDA orphan products research grants.

Open

Funds a genuinely new experimental or computational approach to finding the cause of a rare genetic disorder, where the current state of the art falls short.

Pays an equity-free cash prize to the top healthcare startup pitching live at WHX Tech's Xcelerate competition in Dubai.

Open

Funds theory and method development on how genetic and non-genetic factors together produce variation in complex traits, tested against large existing datasets.

Open

Funds new analysis of clinical, genomic, environmental and registry data that already exists, to sharpen who is at risk of cancer and what happens to them.

Open

Funds the development and hard technical validation that turns a working cancer research technology into one other laboratories will actually adopt.

Open

Funds proof-of-concept work on a genuinely new tool, assay, platform or instrument for characterising cancer cells or handling biospecimens.

Open

Funds the same reanalysis of already-collected cancer data on a smaller, exploratory footing, for teams that do not need a full research project award.

Open

Funds exploratory studies of the ethical, legal and social consequences of human genetics, especially where a technology or a use of genomic data is new.

Open

Funds a full research project on the ethics, law and social effects of human genetics — and refuses to review an application with no diverse-perspectives plan.

Open

Funds one bundled run from first-in-human through phase 2a for a dementia drug that works on something other than amyloid or tau.

Open

Funds the exploratory version of the same theory-and-methods work on complex trait variation, for ideas that need testing before a larger project is justified.